Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
NCT04044937Phase 2Completed
- Start
- Oct 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of O-(2-[18F]fluoroethyl)-L-tyrosine in intracranial neoplasm, low-grade glioma (LGG), glioblastoma (GBM), glioma. Started Oct 2018; status: completed.
02
Drugs
O-(2-[18F]fluoroethyl)-L-tyrosine
03
Conditions
intracranial neoplasmlow-grade glioma (LGG)glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT04044937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044937.